Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Pipeline Review, H2 2016

Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Pipeline Review, H2 2016’, provides in depth analysis on Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted pipeline therapeutics.

The report provides comprehensive information on the Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98)
  • The report reviews Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) Overview
Therapeutics Development
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Products under Development by Stage of Development
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Products under Development by Therapy Area
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Products under Development by Indication
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Products under Development by Companies
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
Chipscreen Biosciences Ltd
GlaxoSmithKline Plc
HitGen LTD
NatureWise Biotech & Medicals Corporation
Sigma-Tau S.p.A.
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Drug Profiles
HG-3001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Largazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NBM-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit HDAC 8 for Pancreatic Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Histone Deacetylases for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-3595 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tucidinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Dormant Projects
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Featured News & Press Releases
Mar 03, 2016: HUYA Bioscience International Expands Senior Management Team
Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan
Sep 03, 2015: HUYA Bioscience International Announces Epigenetic Breast Cancer Program
Aug 27, 2015: HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting
Mar 19, 2015: HUYA Bioscience International Completes First Cohort In Phase 1 Clinical Trial Of HBI-8000 In Japan
Jan 12, 2015: HUYA Bioscience International Announces Regulatory Approval Of Chidamide, The First Selective HDAC Inhibitor In China
Jan 09, 2015: Chipscreen Biosciences Announces CFDA Approval of Chidamide (Epidaza) for PTCLs in China
Jan 08, 2015: HUYA Bioscience International Is The First To Leverage Tripartite Cooperation
Nov 06, 2013: The CSO of Chipscreen Biosciences was invited to speak at “The 4th CPA-RSC Symposium on Medicinal Chemistry: Epigenetics as Targets for Drug Discovery”
Apr 16, 2013: Chipscreen Biosciences Announces Achievement Of Primary Endpoint In Chidamide Registrational Phase II Trial In China
Jul 24, 2012: Chidamide is scheduling to file NDA by the end of this year
Aug 23, 2010: Chidamide (CS055) obtained permission from SFDA to enter into Phase II and III clinic studies for NSCLC, Breast and Prostate cancer in China
Jan 23, 2010: Chidamide (CS055) won US FDA nod to enter into clinic trials in the US
Feb 26, 2009: Chidamide (CS055) won orphan drug designation from SFDA to enter into NDA-directed clinic study for CTCL
Oct 30, 2008: Chipscreen Biosciences and HUYA Bioscience Announce Promising Preclinical and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Number of Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pipeline by Chipscreen Biosciences Ltd, H2 2016
Pipeline by GlaxoSmithKline Plc, H2 2016
Pipeline by HitGen LTD, H2 2016
Pipeline by NatureWise Biotech & Medicals Corporation, H2 2016
Pipeline by Sigma-Tau S.p.A., H2 2016
Dormant Projects, H2 2016
List of Figures
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Top 10 Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook